Clo­vis' Rubra­ca wins prostate can­cer ap­proval, but da­ta from ri­val Lyn­parza damp­en com­mer­cial ex­pec­ta­tions

While As­traZeneca and Mer­ck’s mar­ket-lead­ing Lyn­parza seem­ing­ly pipped Clo­vis On­col­o­gy’s ri­val Rubra­ca in help­ing prostate can­cer pa­tients, Rubra­ca has, as ex­pect­ed, made it across the fin­ish line first.

On Fri­day, the FDA ap­proved Rubra­ca in pa­tients with BR­CA mu­ta­tion-as­so­ci­at­ed metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) who have been treat­ed pre­vi­ous­ly with an­dro­gen re­cep­tor-di­rect­ed ther­a­py as well as chemother­a­py. The ap­proval marks the first ever for a PARP in­hibitor in the prostate can­cer set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER